Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mary Jo Lehman"'
Autor:
Anastasia Ivanova, Beverly S. Mitchell, Marie Green, Anandhi R. Johri, Peter M. Voorhees, Hendrik W. van Deventer, Elizabeth G. Trehu, Dixie Lee Esseltine, Reynaldo Garcia, Fred J. Kudrik, Thomas C. Shea, Julian Adams, Don A. Gabriel, Celeste Lindley, Paul Jones, Melissa D. Hall, E. Claire Dees, Mary Jo Lehman, Robert Z. Orlowski, Tammy Allred, Susan Natoli, Jason M. Collins
Publikováno v:
Blood. 105:3058-3065
Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and p
Autor:
Peter J. Elliott, Owen A. O'Connor, Stephanie Stahl, Steven L. Soignet, Robert Z. Orlowski, Julian Adams, Natalie D. Depcik-Smith, Roberto Guerciolini, Steven C. Novick, Mary Jo Lehman, Jessica K. Anderson, Christine S. Pien, Thomas E. Stinchcombe, Beverly S. Mitchell, Albert S. Baldwin, Dixie Lee Esseltine, Thomas C. Shea, Rita Bhagat
Publikováno v:
Journal of Clinical Oncology. 20:4420-4427
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies. PATIENTS AND MET
Autor:
E. Claire Dees, Reynaldo Garcia, Suzanne E. Biehn, Robert Z. Orlowski, Peter M. Voorhees, Dominic T. Moore, Mary Jo Lehman
Publikováno v:
Annals of hematology. 86(3)
A phase I study of a combination of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin showed significant anti-tumor activity against advanced multiple myeloma, with 36% of patients achieving a complete or near-complete response
Autor:
Mary Jo Lehman, Reynaldo Garcia, Elizabeth Claire Dees, Robert Z. Orlowski, Peter M. Voorhees, Suzanne E. Biehn, Dominic T. Moore
Publikováno v:
Journal of Clinical Oncology. 24:7617-7617
7617 Background: Preclinical studies of bortezomib (bort) with pegylated liposomal doxorubicin (PLD) showed enhanced anti-tumor efficacy compared with either single agent. This led to a phase I trial in patients (pts) with advanced hematologic malign
Autor:
Thomas C. Shea, J.S. Serody, Mary Jo Lehman, G. Rey, D. A. Gabriel, Celeste Lindley, Nelson J. Chao, David A. Rizzieri, Jon P. Gockerman
Publikováno v:
Journal of Clinical Oncology. 23:6700-6700
6700 Background Ifosfamide, Carboplatin and Etoposide (ICE) are commonly used for the treatment of recurrent HD and NHL prior to autologous stem cell transplantation (ASCT). Since maximizing the single agent dose intensity of each component of a comb